Woodley Farra Manion Portfolio Management Inc. Has $28.22 Million Position in Gilead Sciences, Inc. (GILD)
Woodley Farra Manion Portfolio Management Inc. boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.4% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 365,540 shares of the biopharmaceutical company’s stock after purchasing an additional 1,350 shares during the quarter. Gilead Sciences comprises about 2.9% of Woodley Farra Manion Portfolio Management Inc.’s holdings, making the stock its 20th largest position. Woodley Farra Manion Portfolio Management Inc.’s holdings in Gilead Sciences were worth $28,223,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently made changes to their positions in GILD. Bank of New York Mellon Corp raised its stake in Gilead Sciences by 199,789.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 31,350,714 shares of the biopharmaceutical company’s stock valued at $2,420,587,000 after purchasing an additional 31,335,030 shares during the last quarter. Skandinaviska Enskilda Banken AB publ raised its stake in Gilead Sciences by 285.0% in the 3rd quarter. Skandinaviska Enskilda Banken AB publ now owns 3,998,024 shares of the biopharmaceutical company’s stock valued at $308,688,000 after purchasing an additional 2,959,697 shares during the last quarter. Swedbank raised its stake in Gilead Sciences by 103.7% in the 3rd quarter. Swedbank now owns 3,906,172 shares of the biopharmaceutical company’s stock valued at $301,596,000 after purchasing an additional 1,988,987 shares during the last quarter. Natixis raised its stake in Gilead Sciences by 4,550.6% in the 2nd quarter. Natixis now owns 1,913,535 shares of the biopharmaceutical company’s stock valued at $135,555,000 after purchasing an additional 1,872,389 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in Gilead Sciences by 63.1% in the 3rd quarter. Renaissance Technologies LLC now owns 4,489,648 shares of the biopharmaceutical company’s stock valued at $346,646,000 after purchasing an additional 1,737,248 shares during the last quarter. 78.19% of the stock is owned by hedge funds and other institutional investors.
GILD traded down $1.31 during midday trading on Wednesday, hitting $69.55. The company’s stock had a trading volume of 9,768,155 shares, compared to its average volume of 6,488,177. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.45 and a quick ratio of 3.37. The stock has a market capitalization of $93.06 billion, a price-to-earnings ratio of 8.13, a price-to-earnings-growth ratio of -2.75 and a beta of 1.01. Gilead Sciences, Inc. has a 52-week low of $64.27 and a 52-week high of $89.54.
The company also recently announced a quarterly dividend, which will be paid on Friday, December 28th. Stockholders of record on Friday, December 14th will be issued a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.28%. The ex-dividend date of this dividend is Thursday, December 13th. Gilead Sciences’s payout ratio is currently 26.64%.
In other news, Director John C. Martin sold 50,000 shares of the business’s stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $78.04, for a total transaction of $3,902,000.00. Following the completion of the sale, the director now owns 3,067,762 shares in the company, valued at approximately $239,408,146.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 150,000 shares of company stock valued at $10,939,500 in the last quarter. Company insiders own 1.16% of the company’s stock.
GILD has been the subject of several analyst reports. Raymond James reissued a “buy” rating on shares of Gilead Sciences in a research note on Thursday, November 1st. BidaskClub cut Gilead Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, October 24th. Piper Jaffray Companies cut Gilead Sciences from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $85.00 to $75.00 in a report on Friday, October 26th. Evercore ISI restated a “buy” rating on shares of Gilead Sciences in a report on Wednesday, October 31st. Finally, Cantor Fitzgerald initiated coverage on Gilead Sciences in a report on Monday, October 1st. They issued an “overweight” rating and a $87.00 price target for the company. Eleven analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $88.63.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.watchlistnews.com/woodley-farra-manion-portfolio-management-inc-has-28-22-million-position-in-gilead-sciences-inc-gild/2662613.html.
Gilead Sciences Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Further Reading: What does cost of debt say about a company’s financial health?
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.